CommercialCoverageMedium impact
08.02.53, Belantamab mafodotin-blmf (Blenrep)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
A new policy for Belantamab mafodotin-blmf (Blenrep), a specialty oncology drug, has been established for commercial plans. This creates new coverage guidelines and billing requirements for this cancer medication that will take effect in April 2026.
Action Required
Before April 20, 2026: Billing team should obtain the full policy document from the provided URL to understand specific coverage criteria, prior authorization requirements, and billing procedures for Belantamab mafodotin-blmf (Blenrep). Update pharmacy billing protocols and staff training materials accordingly.